Willis’ $1.2bn Tranzact deal likely precludes more big buys in 2019

Willis has followed through on recent signals that it has M&A funds available with the acquisition of Tranzact, a direct-to-consumer healthcare broker, for a price that one estimate said implies 23.7x trailing earnings.